Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$15.67 ▲ +2.28
(+17.03%)
MKT CAP: $2.04B • VOL: 698.6K
52W L $12 52W H $22
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$13
MEDIAN
$18
MEAN
$18
HIGH
$21
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MESO TAPE
MESO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $18.96 | $18.02 | 2025-02-14 | $14.26 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $19.74 | $18.49 | 2025-02-06 | $14.73 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $17.86 | $17.24 | 2025-01-29 | $15.04 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $15.98 | — | 2025-01-17 | $15.36 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $13.79 | $14.89 | 2025-01-09 | $13.95 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $18.65 | $16.30 | 2024-12-18 | $13.63 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $15.20 | $15.83 | 2024-12-04 | $14.57 | -4.3% | 48% | C |